Delivery Order SPE2DB20D2104-SPE2DB22FT72U
- Not listed
- This federal contract award, valued at $12,938.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,406.52 delivery order is for the supply of Xifaxan 550 mg tablets. The contract is a firm fixed-price Delivery Order under a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Amerisourcebergen's parent company, Cencora, Inc. This IDC, valued at up to $999,999,999.00, serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,666.94 firm fixed-price delivery order is for the supply of Xifaxan 550 mg tablets, a specialty medication. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,658.63, is for the delivery of Xifaxan 550 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00. This IDC serves as the primary vehicle for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,271.54, is for the delivery of Xifaxan 550 mg tablets. The contract has a period of performance through November 20, 2024 and utilizes a firm fixed price pricing structure. This award is a delivery order under AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award, valued at $23,835.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Xifaxan 550 mg tablets. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, worth up to $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for the company to provide...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company, for the delivery of Xifaxan 550 mg tablets. The contract has an award value of $5,305.54 and an ultimate completion date of January 12, 2022. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $1,322.83 firm fixed-price delivery order falls under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. (doing business as Amerisourcebergen) and the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,691.88, is for the delivery of Xifaxan 550 mg tablets. This is a Delivery Order contract with a Firm Fixed Price pricing type, with a completion date of December 6, 2023. The contract is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora,...
- This federal contract award is from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,939.51 firm-fixed-price delivery order is for the medication Xifaxan 550 mg tablets. The award has an ultimate completion date of March 26, 2024. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FT72UDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,443.21, is for the delivery of Xifaxan 550 mg tablets. It is a firm fixed-price delivery order contract with an ultimate completion date of August 25, 2022. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds significant Indefinite Delivery Contracts (IDCs) with the DLA Troop Support Medical and the Department of Justice Federal Bureau of Investigation. These IDCs, valued at up to $999,999,999.00 and $750,000.00 respectively, enable the efficient procurement of a comprehensive range of pharmaceutical products and medical supplies to support military, veteran, and other federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 8/24/22 |